Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017 (2017), Article ID 1754741, 7 pages
https://doi.org/10.1155/2017/1754741
Research Article

Nuclear Factor of Activated T Cells and Cytokines Gene Expression of the T Cells in AIDS Patients with Immune Reconstitution Inflammatory Syndrome during Highly Active Antiretroviral Therapy

1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China
2Division of Infectious Diseases, Columbia University Medical Center, New York, NY 10032, USA

Correspondence should be addressed to Biao Zhu; nc.ude.ujz@7021oaibuhz

Received 27 October 2016; Accepted 24 January 2017; Published 20 February 2017

Academic Editor: Vera L. Petricevich

Copyright © 2017 Jia Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. D. Lawn and R. Wood, “Immune reconstitution inflammatory syndrome,” The Lancet Infectious Diseases, vol. 10, no. 12, pp. 833–834, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. A. R. Tappuni, “Immune reconstitution inflammatory syndrome,” Advances in dental research, vol. 23, no. 1, pp. 90–96, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Letang, J. M. Miró, T. Nhampossa et al., “Incidence and predictors of immune reconstitution inflammatory syndrome in a rural area of Mozambique,” PLOS ONE, vol. 6, no. 2, Article ID e16946, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. P. M. Grant, L. Komarow, J. Andersen et al., “Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection,” PLoS ONE, vol. 5, no. 7, Article ID e11416, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. D. M. Murdoch, W. D. F. Venter, C. Feldman, and A. Van Rie, “Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: A Prospective Study,” AIDS, vol. 22, no. 5, pp. 601–610, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Zanoni and F. Granucci, “Regulation and dysregulation of innate immunity by NFAT signaling downstream of pattern recognition receptors (PRRs),” European Journal of Immunology, vol. 42, no. 8, pp. 1924–1931, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. S. D. Lawn and M. A. French, “Immune reconstitution disease: recent developments and implications for antiretroviral treatment in resource-limited settings,” Current Opinion in HIV and AIDS, vol. 2, no. 4, pp. 339–345, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. D. R. Boulware, K. H. Hullsiek, C. E. Puronen et al., “Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death,” Journal of Infectious Diseases, vol. 203, no. 11, pp. 1637–1646, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. B. O. Porter, G. L. Ouedraogo, J. N. Hodge et al., “d-Dimer and CRP levels are elevated prior to antiretroviral treatment in patients who develop IRIS,” Clinical Immunology, vol. 136, no. 1, pp. 42–50, 2010. View at Publisher · View at Google Scholar
  10. S. A. Shelburne, F. Visnegarwala, J. Darcourt et al., “Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy,” AIDS, vol. 19, no. 4, pp. 399–406, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. D. R. Boulware, D. B. Meya, T. L. Bergemann et al., “Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study,” PLoS Medicine, vol. 7, no. 12, Article ID e1000384, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Martin-Blondel, L. T. Mars, and R. S. Liblau, “Pathogenesis of the immune reconstitution inflammatory syndrome in HIV-infected patients,” Current Opinion in Infectious Diseases, vol. 25, no. 3, pp. 312–320, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. S. K. Sharma and M. Soneja, “HIV & immune reconstitution inflammatory syndrome (IRIS),” Indian Journal of Medical Research, vol. 134, no. 12, pp. 866–877, 2011. View at Google Scholar · View at Scopus
  14. J. P. B. Viola and A. Rao, “Molecular regulation of cytokine gene expression during the immune response,” Journal of Clinical Immunology, vol. 19, no. 2, pp. 98–108, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Feske, A. Rao, and P. G. Hogan, “The Ca2+-calcineurin-NFAT signalling pathway,” New Comprehensive Biochemistry, vol. 41, pp. 365–401, 2007. View at Google Scholar
  16. C. Argyropoulos and A. Mouzaki, “Immunosuppressive drugs in HIV disease,” Current Topics in Medicinal Chemistry, vol. 6, no. 16, pp. 1769–1789, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Tadokera, G. Meintjes, K. H. Skolimowska et al., “Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome,” European Respiratory Journal, vol. 37, no. 5, pp. 1248–1259, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. M. E. Franks, G. R. Macpherson, and W. D. Figg, “Thalidomide,” Lancet, vol. 363, no. 9423, pp. 1802–1811, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Xie, J. Sun, J. Su, L. Xu, Y. Huang, and B. Zhu, “Thalidomide for treatment of immune reconstitution inflammatory syndrome in a HIV patient with cutaneous mycobacterium avium complex infection,” Journal of AIDS & Clinical Research, vol. 6, article no. 530, 2015. View at Publisher · View at Google Scholar